The Hague, Netherlands

Nigel G Kooreman

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Nigel G. Kooreman and His Pioneering Cancer Vaccine

Introduction: Nigel G. Kooreman, based in The Hague, Netherlands, is a noted inventor with a focus on innovative medical solutions. With a portfolio that includes a significant patent, he has made remarkable contributions to the field of cancer treatment. His creativity and expertise have established him as a valuable figure in medical research and innovation.

Latest Patents: Kooreman's noteworthy patent is titled "IPSC-based vaccine as a prophylactic and therapeutic treatment for cancer." This groundbreaking invention details a method for treating cancer in patients through vaccination. The vaccine consists of an effective amount of mammalian pluripotent stem cells sourced from either an embryonic origin or by reprogramming somatic cells from the patient. This method not only aims to treat existing cancer but also serves as a preventative measure, showcasing the potential of this innovative approach in oncology.

Career Highlights: Throughout his career, Nigel G. Kooreman has worked with prestigious organizations such as Khloris Biosciences, Inc. and Leland Stanford Junior University. His experiences at these institutions have helped him refine his techniques and further his research initiatives, contributing to his expertise in the domain of stem cell applications in cancer treatment.

Collaborations: Kooreman has collaborated with prominent figures in his field, including colleagues Joseph C. Wu and Lynne Bui. These partnerships have been essential in leveraging diverse insights and expertise, ultimately enriching the research and development process of his innovative cancer vaccine.

Conclusion: Nigel G. Kooreman stands out as a remarkable inventor dedicated to advancing cancer treatment through innovative approaches. His patented IPSC-based vaccine represents a significant leap forward in both therapeutic and prophylactic measures against cancer. As he continues his work in this vital field, the impact of his innovations is expected to resonate within the medical community and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…